Table 2.
Primary and secondary outcomes
| Parameter | Low-dose group (n = 47) | Intermediate-dose group (n = 40) | High-dose group (n = 46) | p-value* |
|---|---|---|---|---|
| Time to clinical response (days) | 4.3 ± 1.9 | 5.3 ± 2.0 | 6.1 ± 3.3 | 0.025 |
| Time to 50% decrease of CRP level (days) | 4.6 ± 2.5 | 5.3 ± 2.4 | 6.0 ± 3.1 | 0.70 |
| Time to respiratory rate ≤ 20 breaths/min (days) | 3.9 ± 1.9 | 3.1 ± 1.8 | 3.8 ± 2.3 | 0.55 |
| Time to SpO2 ≥ 93% (days) | 4.2 ± 2.2 | 4.9 ± 2.7 | 4.9 ± 2.6 | 0.53 |
| Need for mechanical ventilation | 3 (6.4) | 5 (12.5) | 6 (13.0) | 0.51 |
| Duration of mechanical ventilation (days) | 3 ± 2 | 3 ± 2 | 4 ± 3 | 0.99 |
| Duration of hospital stay (days) | 5.7 ± 3.0 | 6.5 ± 3.4 | 7.0 ± 3.6 | 0.17 |
| Need for ICU admission | 5 (10.6) | 5 (12.5) | 9 (19.6) | 0.43 |
| Duration of ICU-stay (days) | 3.2 ± 1.5 | 3.4 ± 1.3 | 5.2 ± 3.4 | 0.17 |
| Hospital readmission | 1 (2.1) | 1 (2.5) | 1 (2.2) | 0.97 |
| 60-day mortality | 8 (17.0) | 12 (30.0) | 19 (41.3) | 0.06 |
Data are presented as n (%) or mean ± SD
*p-value according to one-way ANOVA or Chi-square test